UY34455A - Formulación oral compleja que comprende ácido graso omega 3 e inhibidor de la hmg-coa reductasa con estabilidad mejorada - Google Patents

Formulación oral compleja que comprende ácido graso omega 3 e inhibidor de la hmg-coa reductasa con estabilidad mejorada

Info

Publication number
UY34455A
UY34455A UY0001034455A UY34455A UY34455A UY 34455 A UY34455 A UY 34455A UY 0001034455 A UY0001034455 A UY 0001034455A UY 34455 A UY34455 A UY 34455A UY 34455 A UY34455 A UY 34455A
Authority
UY
Uruguay
Prior art keywords
hmg
inhibitor
fatty acid
improved stability
oral formulation
Prior art date
Application number
UY0001034455A
Other languages
English (en)
Inventor
Jin Cheul Kim
Jae Ho Kim
Eun Jin Yoon
Yong Il Kim
Jae Hyun Park
Jong Soo Woo
Original Assignee
Hanmi Pharm Ind Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Pharm Ind Co Ltd filed Critical Hanmi Pharm Ind Co Ltd
Publication of UY34455A publication Critical patent/UY34455A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)

Abstract

Formulación oral compleja que comprende ácido graso omega 3 o sus derivados encapsulados en una cápsula dura o blanda que contiene: sorbitol y sorbitán, y un inhibidor de la HMG-CoA reductasa. Esta formulación provee una mejor prevención contra la formación de materiales relacionados, lo que provoc a una estabilidad de almacenamiento a largo plazo mejorada. Esta también puede elevar el nivel de colesterol HDL en suero, reduciendo a su vez los niveles de colesterol LDL y de TG. La formulación or al compleja de la presente invención es útil para el tratamiento de la hiperlipidosis.
UY0001034455A 2011-11-17 2012-11-16 Formulación oral compleja que comprende ácido graso omega 3 e inhibidor de la hmg-coa reductasa con estabilidad mejorada UY34455A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20110120493 2011-11-17
KR1020120128926A KR101466617B1 (ko) 2011-11-17 2012-11-14 오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제

Publications (1)

Publication Number Publication Date
UY34455A true UY34455A (es) 2013-06-28

Family

ID=48663604

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034455A UY34455A (es) 2011-11-17 2012-11-16 Formulación oral compleja que comprende ácido graso omega 3 e inhibidor de la hmg-coa reductasa con estabilidad mejorada

Country Status (11)

Country Link
US (1) US20140314844A1 (es)
EP (1) EP2780002A4 (es)
JP (1) JP6073352B2 (es)
KR (1) KR101466617B1 (es)
CN (1) CN103957896A (es)
AR (1) AR088876A1 (es)
HK (1) HK1199396A1 (es)
SA (1) SA112340005B1 (es)
TW (1) TW201328727A (es)
UY (1) UY34455A (es)
WO (1) WO2013073884A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016024844A1 (ko) * 2014-08-13 2016-02-18 한국유나이티드제약 주식회사 오메가-3 지방산 에스테르 및 스타틴계 약물을 포함하는 경구용 복합제제
TWI525110B (zh) * 2014-12-24 2016-03-11 財團法人工業技術研究院 聚合物、及包含其之醫藥組合物
WO2017171484A1 (ko) * 2016-03-31 2017-10-05 한미약품 주식회사 오메가-3 지방산 또는 이의 에스테르, 및 하이드록시메틸글루타릴 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제
KR102108154B1 (ko) * 2017-02-08 2020-05-07 (주)동구바이오제약 개선된 생체이용률을 갖는 오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 약제학적 복합제제

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444784A (en) 1980-08-05 1984-04-24 Merck & Co., Inc. Antihypercholesterolemic compounds
DK149080C (da) 1980-06-06 1986-07-28 Sankyo Co Fremgangsmaade til fremstilling af derivater af ml-236b-carboxylsyre
US5354772A (en) 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
GB8305693D0 (en) * 1983-03-02 1983-04-07 Scherer Ltd R P Pharmaceutical compositions
DE3307353C2 (de) * 1983-03-02 1985-01-31 R.P. Scherer GmbH, 6930 Eberbach Polyethylenglykolhaltige Weichgelatinekapsel und Verfahren zu ihrer Herstellung
US5030447A (en) * 1988-03-31 1991-07-09 E. R. Squibb & Sons, Inc. Pharmaceutical compositions having good stability
US5180589A (en) * 1988-03-31 1993-01-19 E. R. Squibb & Sons, Inc. Pravastatin pharmaceuatical compositions having good stability
GB8819110D0 (en) 1988-08-11 1988-09-14 Norsk Hydro As Antihypertensive drug & method for production
US4963385A (en) * 1989-06-02 1990-10-16 Nabisco Brands, Inc. Stabilized emulsions containing highly unsaturated oils
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5177080A (en) 1990-12-14 1993-01-05 Bayer Aktiengesellschaft Substituted pyridyl-dihydroxy-heptenoic acid and its salts
EP0680320B1 (en) * 1993-01-19 1999-04-14 Warner-Lambert Company Stable oral ci-981 formulation and process of preparing same
GB9313329D0 (en) * 1993-06-28 1993-08-11 Scherer Ltd R P Softgel capsule shell compositions
GB9706149D0 (en) * 1997-03-25 1997-05-14 Scherer Corp R P Comestible capsules having flavoured coatings
SI1292293T1 (en) * 2000-06-09 2004-06-30 LEK farmacevtska dru�ba d.d. Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
US20060078615A1 (en) * 2004-10-12 2006-04-13 Boehringer Ingelheim International Gmbh Bilayer tablet of telmisartan and simvastatin
ES2255426B1 (es) * 2004-10-19 2007-08-16 Gp Pharm, S.A. Formulacion farmaceutica que comprende microcapsulas de estatinas suspendidas en ester alquilicos de acidos grasos poliinsaturados (pufa).
US20060211762A1 (en) * 2004-12-06 2006-09-21 Rongen Roelof M Omega-3 fatty acids and dyslipidemic agent for lipid therapy
EP2081550B2 (en) * 2006-03-09 2021-05-26 Reliant Pharmaceuticals, Inc. Coating capsules with active pharmaceutical ingredients
MX2008016153A (es) * 2006-06-16 2009-01-20 Cipla Ltd Inhalador mejorado de polvo seco.
US20100310650A1 (en) 2006-06-26 2010-12-09 Roberto Valducci Pharmaceutical composition for the oral administration of omega polyenoic fatty acids and one or more active principles incompatible therewith, and a process for its preparation
ITFI20060162A1 (it) * 2006-06-26 2007-12-27 Valpharma Sa Composizione farmaceutica per la somministrazione orale di acidi grassi omega polienoici ed uno o piu' principi attivi con essi incompatibili, e processo per la sua preparazione.
US20100285121A1 (en) * 2008-01-10 2010-11-11 Takeda Pharmaceutical Company Limited Capsule Formulation
WO2009127974A2 (ko) * 2008-02-22 2009-10-22 한올제약주식회사 심혈관계 질환 치료용 약제학적 제제
US8933255B2 (en) * 2008-12-31 2015-01-13 Nitromega Corp. Nutraceuticals containing nitro fatty acids
EP2433630A4 (en) * 2009-05-22 2014-01-08 Mochida Pharm Co Ltd SELF-EMULSIFIABLE COMPOSITION OF FATTY ACID 3

Also Published As

Publication number Publication date
KR20130054921A (ko) 2013-05-27
CN103957896A (zh) 2014-07-30
US20140314844A1 (en) 2014-10-23
JP2014533685A (ja) 2014-12-15
HK1199396A1 (en) 2015-07-03
TW201328727A (zh) 2013-07-16
JP6073352B2 (ja) 2017-02-01
KR101466617B1 (ko) 2014-11-28
SA112340005B1 (ar) 2015-07-09
EP2780002A4 (en) 2015-05-27
EP2780002A1 (en) 2014-09-24
WO2013073884A1 (en) 2013-05-23
AR088876A1 (es) 2014-07-16

Similar Documents

Publication Publication Date Title
UY34395A (es) ?Tratamiento de Esclerosis Múltiple con la Combinación de Laquinimod y Fingolimod?.
UY34587A (es) Formulaciones estabilizadas que contienen anticuerpos antiang2
CO6801750A2 (es) Composición de complejo oral que contiene eter de ácido graso omega-3 e inhibidor de reductasa hmg-coa
UY34721A (es) Anticuerpos anti-hla-b*27 y usos de éstos.
UY34763A (es) Inhibidores de la agregación plaquetaria
UY34779A (es) Anticuerpos anti-il-23 y composiciones farmacéuticas que los contienen
UY33504A (es) N-etil-n-fenil-1,2-dihidro-4-hidroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida deuterada, sales y usos de la misma
MX352328B (es) Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos.
CY1123056T1 (el) Νεα μορφη χορηγησης της ρασεκαδοτριλης
CR20140468A (es) Inhibidores de diacilglicerol aciltransferasa 2
UY34216A (es) Nuevos compuestos que inhiben la actividad de la Lp-PLA2
CO7141409A2 (es) Composiciones tópicas que comprenden fipronilo y permetrina y sus métodos de uso
UY34115A (es) Ensayo de la lisil oxidasa-like 2 y sus métodos de empleo
UY34800A (es) Combinaciones farmacéuticas que contienen un inhibidor de 11-beta-hidroxiesteroide dehidrogenasa-1 útil en trastornos metabólicos
IN2014DN07483A (es)
CO6650346A2 (es) Composiciones de tetraciclina
EP2557919A4 (en) STABILIZED FORMULATIONS OF STATIN
BR112014000256A2 (pt) formulação de microemulsões transparentes e nutritivas
UY34455A (es) Formulación oral compleja que comprende ácido graso omega 3 e inhibidor de la hmg-coa reductasa con estabilidad mejorada
ECSP15050273A (es) Formulación oral para el tratamiento de enfermedades cardiovasculares
UY34552A (es) Forma cristalina delta de la sal de arginina de perindoprilo, su procedimiento de preparación, y las composiciones farmacéuticas que la contienen
BR112013029778A2 (pt) composição farmacêutica que compreende fexofenadina
CL2016000179A1 (es) Formulación de combinación que contiene metformina de liberación prolongada e inhibidor de la hmg-coa reductasa de liberación inmediata.
CY1119482T1 (el) Ιμιδαζολκαρβοξαμιδια και χρηση αυτων ως αναστολεις του faah
UY35004A (es) Forma amorfa estabilizada de la agomelatina, su procedimiento de preparación y las composiciones farmacéuticas que la contienen

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20201020